Adjuvant Chemo Improves Survival in Node-Positive Pancreatic Cancer

Pancreatic cancer has a dismal prognosis with a 5-year survival rate of 9%. Even after upfront surgical resection combined with adjuvant chemotherapy, 75% of patients relapse within 2 years. However, results from a recent study show that adjuvant chemotherapy can improve outcomes in patients with pathology-proven node-positive pancreatic cancer who received neoadjuvant folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and resection, providing a potential new standard of care t...
Continue reading

Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: Alison Birtle, MD

Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a mortality rate of over 50% for locally advanced disease. However, few clinical trials have been conducted due to its low incidence rate. Nephroureterectomy—a surgical procedure in which the renal pelvis, kidney, ureter, and bladder cuff are removed—is considered the standard treatment approach for patients with UTUC, but little research had been conducted regarding the optimal treatment after surgery. In the phase 3 PO...
Continue reading

Upper Tract Urothelial Carcinoma: Adjuvant Chemotherapy Improves Outcomes

In patients with locally advanced upper tract urothelial carcinoma (UTUC), adjuvant platinum-based chemotherapy increases disease-free survival compared with surveillance, according to the results of a phase 3 trial. Due to limited symptoms, the majority of patients with UTUC present with muscle-invasive or locally advanced disease, resulting in a mortality rate of over 50%. Few large clinical trials have been conducted in this space due to the rarity of the disease, and nephroureterectomy—a sur...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.